Interestingly, these observations provide the key evidence that the BRCA2 defect in BRCA2‐mutant tumour cells is the primary driver of Polθi sensitivity, and not some downstream consequence of BRCA2 mutation, such as genomic mutations elsewhere in the genome that have arisen because of the HR defect in these cells. This evidence concerns the gene BRCA2 and neoplasm.